ETTX

Entasis Therapeutics Holdings Inc. [ETTX] Stock Forecast

Q: What is Entasis Therapeutics Holdings Inc. stock symbol ?

Entasis Therapeutics Holdings Inc. is a US stock, located in Waltham of Massachusetts and trading under the symbol ETTX

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

ETTX Stock Summary

EPS has been increasing for the past 3 years (Yearly statements)

The Moving Average Convergence Divergence (MACD) for ETTX recently turned positive (within last 10 days).

ETTX has more than 2 years of cash runway (35 months)

In the last year, shareholders have seen their holdings diluted. Dilution over past year is 28.25%

Debt-to-Equity ratio of 1.13 is considered moderate, deeper research suggested.

In the News

ETTX Financial details

Company Rating

Neutral

Market Cap

Income

-86.83M

Revenue

Book val./share

0.35

Cash/share

0.7

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

10 Aug 2022

P/E

-2.2

Forward P/E

PEG

2.01

P/S

P/B

3.32

P/C

3.13

P/FCF

Quick Ratio

3.33

Current Ratio

4.1

Debt / Equity

1.13

LT Debt / Equity

0.2

EPS (TTM)

-1.87

EPS next Y

EPS next Q

EPS this Y

-52.38%

EPS next Y

EPS next 5Y

EPS last 5Y

Revenue last 5Y

Revenue Q/Q

EPS Q/Q

-68%

SMA20

SMA50

SMA100

Inst Own

11.09%

Inst Trans

1.73%

ROA

-115%

ROE

-113%

ROC

-1.51%

Gross Margin

Oper. Margin

Profit Margin

Payout

Shs Outstand

Shs Float

Target Price

52W Range

52W High

52W Low

RSI

Rel Volume

Avg Volume

Volume

68.83K

Perf Week

Perf Month

Perf Quarter

Perf Half Y

Beta

1.32633

Volatility

0%, 0%

Prev Close

Price

2.19

Change

ETTX Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0	1.46	0.53	0	0
Net income per share	-8.05	-9.64	-3.33	-2.1	-1
Operating cash flow per share	-7.31	-10.47	-3.4	-1.89	-0.91
Free cash flow per share	-7.39	-10.58	-3.41	-1.89	-0.91
Cash per share	14.83	24.88	3.12	2.21	0.68
Book value per share	-15.01	24.24	3.2	2.17	0.66
Tangible book value per share	-15.01	24.24	3.2	2.17	0.66
Share holders equity per share	-15.01	24.24	3.2	2.17	0.66
Interest debt per share	0	0	0.04	0.05	0
Market cap	39.61M	13.92M	65.41M	59.43M	103.61M
Enterprise value	-15.49M	-35.44M	51.2M	7.5M	71.3M
P/E ratio	-1.32	-0.42	-1.49	-1.18	-2.2
Price to sales ratio	0	2.78	9.34	0	0
POCF ratio	-1.46	-0.39	-1.46	-1.31	-2.41
PFCF ratio	-1.44	-0.38	-1.46	-1.31	-2.41
P/B Ratio	-0.71	0.17	1.55	1.14	3.32
PTB ratio	-0.71	0.17	1.55	1.14	3.32
EV to sales	0	-7.09	7.31	0	0
Enterprise value over EBITDA	0.52	1.1	-1.19	-0.15	-1.52
EV to operating cash flow	0.57	0.99	-1.14	-0.17	-1.66
EV to free cash flow	0.56	0.98	-1.14	-0.17	-1.66
Earnings yield	-0.76	-2.37	-0.67	-0.85	-0.45
Free cash flow yield	-0.69	-2.6	-0.69	-0.76	-0.42
Debt to equity	0	0	0.01	0.03	0
Debt to assets	0	0	0.01	0.02	0
Net debt to EBITDA	1.85	1.53	0.33	1.03	0.69
Current ratio	5.73	14.28	6.49	7.02	4.1
Interest coverage	0	0	0	0	0
Income quality	0.91	1.09	1.02	0.9	0.91
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	2.03	1.97	0	0
Research and developement to revenue	0	6.61	5.74	0	0
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0.01	0.01	0	0	0
Capex to revenue	0	-0.07	-0.02	0	0
Capex to depreciation	-1.47	-2.26	-0.74	-0.13	-0.67
Stock based compensation to revenue	0	0.24	0.35	0	0
Graham number	52.16	72.49	15.5	10.13	3.85
ROIC	0.59	-0.47	-1.07	-1.06	-1.51
Return on tangible assets	-0.51	-0.37	-0.86	-0.82	-1.15
Graham Net	-15.86	23.39	2.51	1.89	0.48
Working capital	46.49M	82.58M	41.45M	51.57M	30.11M
Tangible asset value	-55.79M	82.88M	42.16M	52.29M	31.21M
Net current asset value	-58.26M	82.4M	40.13M	50.86M	30.11M
Invested capital	0	0	0.01	0.03	0
Average receivables	478K	1.21M	1.47M	1.56M	945K
Average payables	1.56M	1.79M	1.34M	982K	921.5K
Average inventory	0	0	0	0	0
Days sales outstanding	0	124.54	64.24	0	0
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	2.93	5.68	0	0
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	0.54	-0.4	-1.04	-0.97	-1.51
Capex per share	-0.08	-0.11	-0.01	0	0

Quarterly Fundamentals Overview

Last date of statement is 2022-03-31 for Q1

Metric	2021-03-31	2021-06-30	2021-09-30	2021-12-31	2022-03-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0	0	0	0	0
Net income per share	-0.29	-0.29	-0.26	-1	-0.32
Operating cash flow per share	-0.27	-0.21	-0.26	-0.26	-0.29
Free cash flow per share	-0.27	-0.21	-0.26	-0.26	-0.29
Cash per share	1.21	1.37	0.93	0.68	0.7
Book value per share	1.19	1.29	0.87	0.66	0.35
Tangible book value per share	1.19	1.29	0.87	0.66	0.35
Share holders equity per share	1.19	1.29	0.87	0.66	0.35
Interest debt per share	0.03	0.02	0.02	0	0.39
Market cap	79.35M	109.76M	158.02M	103.61M	89.48M
Enterprise value	35.58M	54.37M	114.76M	71.3M	74.79M
P/E ratio	-1.85	-2.28	-3.19	-0.55	-1.46
Price to sales ratio	0	0	0	0	0
POCF ratio	-7.86	-12.94	-13.06	-8.43	-6.51
PFCF ratio	-7.85	-12.9	-13.02	-8.43	-6.5
P/B Ratio	1.79	2.07	3.83	3.32	5.38
PTB ratio	1.79	2.07	3.83	3.32	5.38
EV to sales	0	0	0	0	0
Enterprise value over EBITDA	-3.33	-4.53	-9.28	-1.51	-4.91
EV to operating cash flow	-3.52	-6.41	-9.49	-5.8	-5.44
EV to free cash flow	-3.52	-6.39	-9.46	-5.8	-5.44
Earnings yield	-0.13	-0.11	-0.08	-0.45	-0.17
Free cash flow yield	-0.13	-0.08	-0.08	-0.12	-0.15
Debt to equity	0.03	0.02	0.02	0	1.13
Debt to assets	0.02	0.02	0.02	0	0.43
Net debt to EBITDA	4.1	4.61	3.5	0.69	0.96
Current ratio	6.42	6.15	5.32	4.1	1.65
Interest coverage	0	0	0	0	-1.53K
Income quality	0.94	0.71	0.98	0.26	0.9
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0	0	0	0	0
Capex to revenue	0	0	0	0	0
Capex to depreciation	-0.39	-0.81	-1.54	0	-0.38
Stock based compensation to revenue	0	0	0	0	0
Graham number	2.78	2.92	2.27	3.85	1.58
ROIC	-0.32	-0.27	-0.35	-1.51	-0.39
Return on tangible assets	-0.2	-0.19	-0.24	-1.15	-0.35
Graham Net	1.03	1.17	0.78	0.48	0.15
Working capital	43.51M	52.28M	40.4M	30.11M	15.74M
Tangible asset value	44.26M	53.06M	41.24M	31.21M	16.65M
Net current asset value	42.98M	51.92M	40.22M	30.11M	12.44M
Invested capital	0.03	0.02	0.02	0	1.13
Average receivables	2.22M	2.61M	2.81M	1.48M	573K
Average payables	547K	739.5K	1.09M	1.16M	1.48M
Average inventory	0	0	0	0	0
Days sales outstanding	0	0	0	0	0
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0	0	0	0
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	-0.24	-0.23	-0.3	-1.51	-0.92
Capex per share	0	0	0	0	0

ETTX Frequently Asked Questions

What is Entasis Therapeutics Holdings Inc. stock symbol ?

Entasis Therapeutics Holdings Inc. is a US stock , located in Waltham of Massachusetts and trading under the symbol ETTX

What is Entasis Therapeutics Holdings Inc. stock quote today ?

Entasis Therapeutics Holdings Inc. stock price is $2.19 today.

Is Entasis Therapeutics Holdings Inc. stock public?

Yes, Entasis Therapeutics Holdings Inc. is a publicly traded company.

Something similar

Top by Market Cap

Same Sector

Check Those

Similar Market Cap

Company Profile

Employee 51
CEO Dr. Manoussos Perros
Headquarters Waltham,MASSACHUSETTS,US
IPO Date 2018-09-26
Website https://www.entasistx.com

Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial products to treat serious infections caused by multidrug-resistant pathogens in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant gram-negative infections. The company has a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. for the development of durlobactam and SUL-DUR; and collaboration agreement with Global Antibiotic Research and Development Partnership for the development and commercialization of a product candidate zoliflodacin. Entasis Therapeutics Holdings Inc. was founded in 2015 and is headquartered in Waltham, Massachusetts. Entasis Therapeutics Holdings Inc. operates as a subsidiary of Innoviva, Inc.